C

ritics have excoriated Sarepta Therapeutics (SRPT) for winning FDA approval for a drug to treat Duchenne muscular dystrophy despite scant scientific proof that it helps patients suffering from the inherited, muscle-wasting disease.

Sarepta has long insisted the doubters are wrong. And on Wednesday, the biotech firm strengthened its case with data from a new clinical trial: A second Sarepta drug, designed to treat another form of Duchenne muscular dystrophy, is producing significantly larger quantities of dystrophin, a crucial muscle protein normally missing in these patients.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.